Matt is a postdoctoral researcher in the Garnett laboratory focussing on functional genomics strategies to understand molecular pathways involved in sensitivity to cancer immunotherapies. Matt has gained prior expertise in cancer immunotherapy in the laboratory of Julian Downward at the Francis Crick Institute, and CRISPR and Base Editing technologies at AstraZeneca.
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B.
BMC biology 2018;16;1;150
Involvement of a eukaryotic-like ubiquitin-related modifier in the proteasome pathway of the archaeon Sulfolobus acidocaldarius.
Nature communications 2015;6;8163